- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05238740
Comparison of Standalone Anterior Lumbar Interbody Fusion (ALIF) L5/S1 Performed With Either rhBMP-2 or ViviGen®
Comparison of Radiographic Fusion Rate & Clinical Outcome of Standalone ALIF L5/S1 Performed With Either rhBMP-2 or ViviGen® Cellular Bone Matrix, a Prospective Randomized Assessor Blind, Monocentric Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
The investigator hypothesize that the intervention group administered ViviGen® would, following surgery, experience:
- Comparable bony fusion rates, evaluated via CT scan one year postoperatively
- Comparable clinical outcome/ simplified COMI-score one year postoperatively
- Comparable/ less inpatient length of stay (LOS)
- Comparable/ less healthcare costs one year postoperatively
For patients included in the study, all follow-up is recorded, with regards to radiological and clinical outcome. Follow up will be evaluated after 14 days, 6 weeks, 6 and 12 months. Last follow up will be 1 year after surgery.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Diel Peter, Dr. med
- Phone Number: +41 31 358 17 90
- Email: peter.diel@sonnenhof.ch
Study Contact Backup
- Name: Sabine Berger
- Phone Number: +41 79 328 50 24
- Email: sabine.berger@lindenhofgruppe.ch
Study Locations
-
-
-
Bern, Switzerland, 3006
- Recruiting
- Orthopädie Sonnenhof
-
Contact:
- Peter Diel, Dr.med.
- Phone Number: +41 31 358 17 90
- Email: peter.diel@sonnenhof.ch
-
Contact:
- Sabine Berger
- Phone Number: +41793285024
- Email: sabine.berger@lindenhofgruppe.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients that present the indication for performing ALIF procedure L5/S1 (incl. stabilizations), e.g.,treating conditions such as spondylosis, spondylolisthesis and degenerative disc disorders with back and/or leg pain
- Patients must be 18 -70 years of age
- Patients must have understood and signed the study information and the informed consent form
- Patients are willing and able to complete scheduled follow-up evaluations / questionnaires as described in the Informed Consent
Exclusion Criteria:
- Patients under 18 years and over 70 of age
- Patients with tumor/ spine trauma/ known bone disease / parkinsons disease and similar central nervous system (CNS) disorders / diseases or injuries of the peripheral nerves
- Other procedures than ALIF and other lumbar segments than L5/S1
- Current Smoking
- Pregnant or breastfeeding patients
- inadequate language skills in German
- Inability to give informed consent
- Refusal to participate in the study, unsigned study consent
- Participation in another interventional study within the 30 days preceding and during the present study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Intervention group 5-5.4 cc ViviGen®
Biological: 5-5.4 cc ViviGen®The stand-alone ALIF L5/S1 fusion patients assigned to this group will receive 5-5.4 cc ViviGen®
|
It will investigate the radiological and clinical outcome of stand-alone ALIF procedure L5/S1 using two arms/ treatments, namely either ViviGen® Bone Matrix (intervention group) or rhBMP-2 (control group).
ViviGen®/ rhBMP-2 ratio will be 1:1.
|
Active Comparator: Control group 4-6mg rhBMP-2
Biological: 4-6mg rhBMP-2The stand-alone ALIF L5/S1 fusion patients assigned to this group will receive 4-6mg rhBMP-2
|
It will investigate the radiological and clinical outcome of stand-alone ALIF procedure L5/S1 using two arms/ treatments, namely either ViviGen® Bone Matrix (intervention group) or rhBMP-2 (control group).
ViviGen®/ rhBMP-2 ratio will be 1:1.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of interbody bony fusion in the lumbar segment L5/S1 using Brantigan, Steffee, Fraser (BSF)
Time Frame: 12 months after intervention
|
The rate of interbody bony fusion will be assessed by computed tomography and then by a radiologist 12 months after the intervention. Modified Brantigan, Steffee, Fraser (BSF) classification of interbody fusion success will be defined as follows: BSF-1: Radiographical pseudarthrosis is indicated by collapse of the construct, loss of disc height, vertebral slip, broken screws, displacement of the Synfix cage, or significant resorption of the bone graft, or lucency visible around the periphery of the graft or cage. BSF-2: Radiographical locked pseudarthrosis is indicated by lucency visible in the middle of the cages with solid bone growing into the cage from each vertebral endplate. BSF-3: Radiographical fusion: bone bridges at least half of the fusion area with at least the density originally achieved at surgery. Radiographical fusion through one cage (half of the fusion area) is considered to be mechanically solid fusion even if there is lucency on the opposite side. |
12 months after intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Back pain visual analogue scale
Time Frame: before intervention and at 6 weeks, 6 months and 12 months after intervention
|
The back pain visual analogue scale (VAS 1-10) will be assessed before intervention and at 6 weeks, 6 months and 12 months after intervention.
|
before intervention and at 6 weeks, 6 months and 12 months after intervention
|
Leg pain visual analogue scale
Time Frame: before intervention and at 6 weeks, 6 months and 12 months after intervention
|
The leg pain visual analogue scale (VAS 1-10) will be assessed before intervention and at 6 weeks, 6 months and 12 months after intervention.
|
before intervention and at 6 weeks, 6 months and 12 months after intervention
|
Quality of life using a simplified Spine Tango questionnaire and the Core Outcome Measures Index (COMI Score)
Time Frame: before intervention and at 6 weeks, 6 months and 12 months after intervention
|
Quality of life will be assessed by using a simplified Spine Tango questionnaire and the Core Outcome Measures Index (COMI Score) before intervention and at 6 weeks, 6 months and 12 months after intervention.
|
before intervention and at 6 weeks, 6 months and 12 months after intervention
|
Disability/ limitations in the activities of daily living using a simplified Spine Tango questionnaire and the Core Outcome Measures Index (COMI Score)
Time Frame: before intervention and at 6 weeks, 6 months and 12 months after intervention
|
Disability / limitations in the activities of daily living will be assessed by using a simplified Spine Tango questionnaire and the Core Outcome Measures Index (COMI Score) before intervention and at 6 weeks, 6 months and 12 months after intervention.
|
before intervention and at 6 weeks, 6 months and 12 months after intervention
|
Disability/ limitations at the workplace using a simplified Spine Tango questionnaire and the Core Outcome Measures Index (COMI Score)
Time Frame: before intervention and at 6 weeks, 6 months and 12 months after intervention
|
Disability / limitations at the workplace will be assessed by using a simplified Spine Tango questionnaire and the Core Outcome Measures Index (COMI Score) before intervention and at 6 weeks, 6 months and 12 months after intervention.
|
before intervention and at 6 weeks, 6 months and 12 months after intervention
|
Patient satisfaction using a simplified Spine Tango questionnaire and the Core Outcome Measures Index (COMI Score)
Time Frame: 6 weeks, 6 months and 12 months after intervention
|
Patient satisfaction will be assessed by using a simplified Spine Tango questionnaire and the Core Outcome Measures Index (COMI Score) at 6 weeks, 6 months and 12 months after intervention.
|
6 weeks, 6 months and 12 months after intervention
|
Complication / side effects using a simplified Spine Tango questionnaire and the Core Outcome Measures Index (COMI Score)
Time Frame: 14 days, 6 weeks, 6 months and 12 months after intervention
|
Complication / side effects will be assessed by using a simplified Spine Tango questionnaire and the Core Outcome Measures Index (COMI Score) at 14 days, 6 weeks, 6 months and 12 months after intervention.
|
14 days, 6 weeks, 6 months and 12 months after intervention
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Healthcare-costs using hospitalisation length of stay (LOS), occurrence and therapy of side effects/ adverse events and necessary revision operations
Time Frame: 12 months after intervention
|
Healthcare-costs will be assessed by using hospitalisation length of stay (LOS), occurrence and therapy of side effects/ adverse events and necessary revision operations at 12 months after intervention.
|
12 months after intervention
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Diel Peter, Dr. med., Orthopädie Sonnenhof, Bern
Publications and helpful links
General Publications
- Kadam A, Millhouse PW, Kepler CK, Radcliff KE, Fehlings MG, Janssen ME, Sasso RC, Benedict JJ, Vaccaro AR. Bone substitutes and expanders in Spine Surgery: A review of their fusion efficacies. Int J Spine Surg. 2016 Sep 22;10:33. doi: 10.14444/3033. eCollection 2016.
- Arrington ED, Smith WJ, Chambers HG, Bucknell AL, Davino NA. Complications of iliac crest bone graft harvesting. Clin Orthop Relat Res. 1996 Aug;(329):300-9. doi: 10.1097/00003086-199608000-00037.
- Birmingham E, Niebur GL, McHugh PE, Shaw G, Barry FP, McNamara LM. Osteogenic differentiation of mesenchymal stem cells is regulated by osteocyte and osteoblast cells in a simplified bone niche. Eur Cell Mater. 2012 Jan 12;23:13-27. doi: 10.22203/ecm.v023a02.
- Johnstone B, Zhang N, Waldorff EI, Semler E, Dasgupta A, Betsch M, Punsalan P, Cho H, Ryaby JT, Yoo J. A Comparative Evaluation of Commercially Available Cell-Based Allografts in a Rat Spinal Fusion Model. Int J Spine Surg. 2020 Apr 30;14(2):213-221. doi: 10.14444/7026. eCollection 2020 Apr.
- Manzur M, Virk SS, Jivanelli B, Vaishnav AS, McAnany SJ, Albert TJ, Iyer S, Gang CH, Qureshi S. The rate of fusion for stand-alone anterior lumbar interbody fusion: a systematic review. Spine J. 2019 Jul;19(7):1294-1301. doi: 10.1016/j.spinee.2019.03.001. Epub 2019 Mar 11.
- Singh K, Ahmadinia K, Park DK, Nandyala SV, Marquez-Lara A, Patel AA, Fineberg SJ. Complications of spinal fusion with utilization of bone morphogenetic protein: a systematic review of the literature. Spine (Phila Pa 1976). 2014 Jan 1;39(1):91-101. doi: 10.1097/BRS.0000000000000004.
- Wetzell B, McLean JB, Moore MA, Kondragunta V, Dorsch K. A large database study of hospitalization charges and follow-up re-admissions in US lumbar fusion surgeries using a cellular bone allograft (CBA) versus recombinant human bone morphogenetic protein-2 (rhBMP-2). J Orthop Surg Res. 2020 Nov 19;15(1):544. doi: 10.1186/s13018-020-02078-7.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-02219
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Degenerative Disc Disease
-
Assistance Publique - Hôpitaux de ParisTerminatedCervical Degenerative Disc Disease | Kyphosis | Lumbar Degenerative Disc DiseaseFrance
-
Assiut UniversityNot yet recruiting
-
Spine BioPharma, IncMCRARecruitingLumbar Degenerative Disc DiseaseUnited States
-
AxioMed Spine CorporationUnknownDegenerative Disc Disease (DDD)United States, Germany
-
Synthes USA HQ, Inc.CompletedLumbar Degenerative Disc Disease
-
DePuy InternationalTerminatedCervical Degenerative Disc DiseaseAustralia, Germany, Italy, Malaysia, Netherlands, Spain, United Kingdom
-
Synergy Spine SolutionsMCRARecruitingCervical Degenerative Disc DiseaseUnited States
-
Orthofix Inc.TerminatedCervical Degenerative Disc DiseaseUnited States
-
Yuhan CorporationCompletedDisc Degenerative DiseaseKorea, Republic of
-
ReGelTec, Inc.Not yet recruitingDegenerative Disc Disease (DDD)
Clinical Trials on ViviGen®
-
DePuy SpineCompletedHerniated Disc | Cervical Spondylosis | Degenerative Intervertebral Discs
-
University of VirginiaDePuy SynthesEnrolling by invitationAnkle Deformity | Ankle ArthritisUnited States
-
Ohio State UniversityDePuy SynthesTerminatedDegenerative Disc Disease | Spinal Stenosis | Spondylosis | SpondylolisthesisUnited States
-
William Beaumont HospitalsDePuy SynthesActive, not recruitingDegenerative Disc Disease | Lumbar Spinal Stenosis | Lumbar Spondylolisthesis | Lumbar Radiculopathy | Lumbar Disc Disease | Degenerative SpondylolisthesisUnited States
-
LifeNet HealthRecruitingFractures, Bone | Nonunion of Fracture | Fractures, Ununited | Fractures, Open | Fracture of Femur | Fracture, Tibial | Fracture ArmUnited States
-
Virtua Health, Inc.Terminated
-
Dong-A ST Co., Ltd.CompletedFunctional DyspepsiaKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompleted
-
Galderma R&DCompletedAtopic DermatitisPhilippines, China
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Diphtheria | PolioUnited States